

# Alain Dekker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1806967/publications.pdf>

Version: 2024-02-01

22  
papers

586  
citations

840776

11  
h-index

713466

21  
g-index

24  
all docs

24  
docs citations

24  
times ranked

758  
citing authors

#	ARTICLE	IF	CITATIONS
1	Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. <i>Cortex</i> , 2015, 73, 36-61.	2.4	201
2	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. <i>Current Alzheimer Research</i> , 2016, 13, 1145-1164.	1.4	50
3	DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. <i>Scientific Reports</i> , 2018, 8, 2859.	3.3	49
4	Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 45, 72-84.	6.1	47
5	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 797-819.	2.6	38
6	Serum MHPG Strongly Predicts Conversion to Alzheimer's Disease in Behaviorally Characterized Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 871-891.	2.6	32
7	Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 1-10.	2.4	28
8	Serum NGAL is Associated with Distinct Plasma Amyloid- $\beta$ Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 733-743.	2.6	17
9	Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society. <i>Molecular Syndromology</i> , 2016, 7, 251-261.	0.8	16
10	Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models. <i>Neurobiology of Disease</i> , 2017, 105, 235-244.	4.4	14
11	Translating molecular advances in Down syndrome and Fragile X syndrome into therapies. <i>European Neuropsychopharmacology</i> , 2018, 28, 675-690.	0.7	14
12	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation <sup>1</sup> . <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1505-1527.	2.6	14
13	The neglected puzzle of dementia in people with severe/profound intellectual disabilities: A systematic literature review of observable symptoms. <i>Journal of Applied Research in Intellectual Disabilities</i> , 2022, 35, 24-45.	2.0	14
14	Dementia in people with severe or profound intellectual (and multiple) disabilities: Focus group research into relevance, symptoms and training needs. <i>Journal of Applied Research in Intellectual Disabilities</i> , 2021, 34, 1602-1617.	2.0	10
15	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 99-111.	2.4	9
16	Phosphorylation of AMPA-Type Glutamate Receptors: The Trigger of Epileptogenesis?. <i>Journal of Neuroscience</i> , 2013, 33, 5879-5880.	3.6	8
17	Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society. <i>Molecular Syndromology</i> , 2018, 9, 279-286.	0.8	8
18	Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society. <i>Molecular Syndromology</i> , 2021, 12, 202-218.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Detecting sleep apnea in adults with Down syndrome using WatchPAT: A feasibility study. Research in Developmental Disabilities, 2022, 129, 104302.	2.2	4
20	Dementia in People with Severe/Profound Intellectual (and Multiple) Disabilities: Practice-Based Observations of Symptoms. Journal of Mental Health Research in Intellectual Disabilities, 2022, 15, 364-393.	2.0	1
21	P1-167: SERUM LIPOCALIN-2: MONITORING THE NEUROPATHOLOGICAL PROGRESSION OF AD IN DOWN SYNDROME?. , 2014, 10, P361-P361.		0
22	Epigenetics and Down syndrome. , 2017,, 163-184.		0